Participants taking the highest dose lost an average of 28.7% of their body weight over 68 weeksroughly 60 to 71 pounds for many participants
Turn ordinary foods into functional superfoods with GLP-1 Daily Support, a 4-in-1 prebiotic blend that naturally aids appetite control, blood sugar balance, and metabolic health
Key Takeaways Retatrutide (LY3437943) is an investigational weight loss medication developed by Eli Lilly Triple-agonist mechanism: First drug to activate GLP-1, GIP, and glucagon receptors simultaneously Phase 2 results: Up to 24.2% weight loss at 48 weeks (approximately 58 lbs for a 240-lb person) Not FDA-approved: Currently in Phase 3 clinical trials, expected approval in 20272028 How it differs: Outperforms semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) in weight loss trials Access now: Clinical trials (free), compounding pharmacies, or research peptide vendors What Is Retatrutide
A previous study highlighted that they increase nitric oxide production, reduce oxidative stress and promote microvascular recruitment, including in the retina and optic nerve, through direct actions on vascular endothelium
Each production batch undergoes analytical verification to ensure consistent molecular composition, helping support reproducible performance in receptor assays, biochemical studies, and other laboratory research applications
